Business
Trading to commence on the OTCQB in the US
Abingdon Health plc will commence trading on the OTCQB Venture Market in the United States on April 21, 2026, under the ticker symbol ABDXF, while continuing to trade on AIM as ABDX. This expansion into the US market follows the second phase of a facility expansion at its Madison, Wisconsin site, which aims to provide manufacturing capabilities in both the USA and UK to offer customers geographic optionality and address supply chain uncertainties. The company anticipates this move will increase its relevance to US investors, enhance share liquidity, and benefit existing investors without incurring additional reporting obligations or significant ongoing costs. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n\n \nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\n \nTrading to commence on the OTCQB Venture Market in the US\n \nYork, UK and Madison, WI, USA, 14 April 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that following the announcement made on 10 March 2026, trading in the Company's ordinary shares will begin from 21 April 2026 on the OTCQB Venture Market (\"OTCQB\") in the United States, under the ticker symbol \"ABDXF\".\n \nAbingdon Health announced the second phase of a facility expansion at its Madison, Wisconsin (US) site in September 2025. Having raised the proceeds to support and expedite this growth in October 2025, this build-out will complement Abingdon Health's UK operations to allow manufacturing for customers under the same conditions and quality management system in either the USA, the UK, or both. The US expansion will provide customers with unrivalled geographic optionality during a period of tariff and supply chain uncertainty and provides US customers with the knowledge that their products \"developed in the USA\" by the Company's highly skilled CDMO team can also be \"made in the USA\".\n \nThe OTCQB is designed for entrepreneurial and development stage US and international companies. Foreign Private Issuers, such as Abingdon Health, that trade on the OTCQB are exempt under the US Exchange Act Rule 12g3-2(b) from SEC reporting if they make whatever information is required by their home market regulator publicly available to US investors in English. Abingdon Health will therefore face no extra reporting obligations and incur minimal ongoing costs as a result of the Company's Ordinary Shares being traded on the OTCQB. \n \nAbingdon Health's Ordinary Shares will continue to trade on the London Stock Exchange's AIM Market under the symbol \"ABDX\".\n \nChris Hand, Executive Chairman, commented: \"Having seen our physical footprint and customer portfolio grow in the US following the establishment and expansion of our facility in Madison, Wisconsin, we believe that Abingdon Health is becoming increasingly relevant to US investors. This OTCQB launch will not only make our shares accessible to investors in ...